These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19147251)

  • 1. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
    Lexchin J
    Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incentive formularies and changes in prescription drug spending.
    Landon BE; Rosenthal MB; Normand SL; Spettell C; Lessler A; Underwood HR; Newhouse JP
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):360-9. PubMed ID: 17567237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?
    Gafni A; Birch S
    CMAJ; 2003 Apr; 168(7):849-51. PubMed ID: 12668543
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors.
    Wang YR; Pauly MV
    Manag Care Interface; 2005 Aug; 18(8):39-45. PubMed ID: 16127891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference pricing and firms' pricing strategies.
    Miraldo M
    J Health Econ; 2009 Jan; 28(1):176-97. PubMed ID: 19038465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How complete are drug history profiles that are based on public drug benefit claims?
    Paterson JM; Suleiman A; Hux JE; Bell C
    Can J Clin Pharmacol; 2008; 15(1):e108-16. PubMed ID: 18283220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should cost-effectiveness take the blame?
    McGregor M
    CMAJ; 2003 Jun; 168(12):1528; author reply 1528-9. PubMed ID: 12796326
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dilemmas of the pharmacist, 7th edition of Hungarian National Formulary in practice].
    Pál S
    Acta Pharm Hung; 2005; 75(4):199-203. PubMed ID: 16711397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized medications.
    Koo V
    CMAJ; 2001 Nov; 165(11):1467-8. PubMed ID: 11762567
    [No Abstract]   [Full Text] [Related]  

  • 13. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of economic evaluation in the listing and pricing of pharmaceuticals].
    Lee TJ
    J Prev Med Public Health; 2008 Mar; 41(2):69-73. PubMed ID: 18385545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of obtaining medications from pharmaceutical company assistance programs on therapeutic goals.
    Trompeter JM; Havrda DE
    Ann Pharmacother; 2009 Mar; 43(3):469-77. PubMed ID: 19240259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
    Lexchin J
    Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
    Mullins CD; Palumbo FB; Saba M
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.